Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/105324
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Carvalho, Laura Sofia | - |
dc.contributor.author | Gonçalves, Nélio | - |
dc.contributor.author | Fonseca, Nuno André | - |
dc.contributor.author | Moreira, João Nuno | - |
dc.date.accessioned | 2023-02-17T09:14:45Z | - |
dc.date.available | 2023-02-17T09:14:45Z | - |
dc.date.issued | 2021-01-13 | - |
dc.identifier.issn | 1424-8247 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/105324 | - |
dc.description.abstract | Cancer, one of the most mortal diseases worldwide, is characterized by the gain of specific features and cellular heterogeneity. Clonal evolution is an established theory to explain heterogeneity, but the discovery of cancer stem cells expanded the concept to include the hierarchical growth and plasticity of cancer cells. The activation of epithelial-to-mesenchymal transition and its molecular players are widely correlated with the presence of cancer stem cells in tumors. Moreover, the acquisition of certain oncological features may be partially attributed to alterations in the levels, location or function of nucleolin, a multifunctional protein involved in several cellular processes. This review aims at integrating the established hallmarks of cancer with the plasticity of cancer cells as an emerging hallmark; responsible for tumor heterogeneity; therapy resistance and relapse. The discussion will contextualize the involvement of nucleolin in the establishment of cancer hallmarks and its application as a marker protein for targeted anticancer therapies. | pt |
dc.language.iso | eng | pt |
dc.publisher | MDPI | pt |
dc.relation | POCI-01-0145-FEDER-016390 | pt |
dc.relation | CENTRO-01-0145- FEDER-000012-HealthyAging2020 | pt |
dc.relation | Euronanomed (FCT reference ENMed/0005/2015) | pt |
dc.relation | UIDB/04539/2020 | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | tumor heterogeneity | pt |
dc.subject | drug resistance | pt |
dc.subject | cancer stem cells | pt |
dc.subject | nucleolin | pt |
dc.subject | targeted therapies | pt |
dc.subject | epithelial-to-mesenchymal transition | pt |
dc.title | Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis | pt |
dc.type | article | - |
degois.publication.firstPage | 60 | pt |
degois.publication.issue | 1 | pt |
degois.publication.title | Pharmaceuticals | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.3390/ph14010060 | pt |
degois.publication.volume | 14 | pt |
dc.date.embargo | 2021-01-13 | * |
uc.date.periodoEmbargo | 0 | pt |
item.languageiso639-1 | en | - |
item.fulltext | Com Texto completo | - |
item.grantfulltext | open | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | article | - |
item.cerifentitytype | Publications | - |
crisitem.project.grantno | Center for Innovative Biomedicine and Biotechnology - CIBB | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
Appears in Collections: | I&D CNC - Artigos em Revistas Internacionais I&D CIBB - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Cancer-stem-cells-and-nucleolin-as-drivers-of-carcinogenesisPharmaceuticals.pdf | 1.89 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
30
checked on Oct 14, 2024
WEB OF SCIENCETM
Citations
26
checked on Oct 2, 2024
Page view(s)
88
checked on Nov 5, 2024
Download(s)
32
checked on Nov 5, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License